I think you are missing my point. I don’t think Teva has recreated MNTA’s technology. I’m not really sure how they would do that and to your point would be in violation of every MNTA patent. My point is that MNTA has a lot of patents and some of them may be broad, I don’t really know. My question (as an example) is can one characterize LMWH to FDA standards without doing chain profiles or chain mapping? If no, then how many ways can one chain map a LMWH? Are the MNTA patents broad enough to prevent any other chain mapping? If they are Teva and any other generic player will have IP issues. I think it would be similar to MNTA having patents on certain assays or testing methods that are required for lot release.
Market Data 
Markets 
AI
